Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$446.88 10.07 (2.2%) as of 4:30 Tue 5/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 116.21(B)
Last Volume: 1,379,606 Avg Vol: 1,610,683
52 Week Range: $323.57 - $450.8
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 23,137 144,475 259,873 619,971
Total Sell Value $10,319,530 $60,539,246 $102,205,755 $209,876,745
Total People Sold 7 12 14 18
Total Sell Transactions 7 40 65 130
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 3274
  Page 4 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-09 4 D $422.74 $351,720 D/D (832) 24,050     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-09 4 D $422.74 $887,754 D/D (2,100) 46,810     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-09 4 D $422.74 $3,489,719 D/D (8,255) 162,271     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-09 4 D $422.74 $887,754 D/D (2,100) 68,493     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-09 4 D $422.74 $887,331 D/D (2,099) 50,733     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-09 4 D $422.74 $249,839 D/D (591) 11,050     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-09 4 D $422.74 $3,402,212 D/D (8,048) 30,300     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-08 4 D $421.73 $1,137,828 D/D (2,698) 38,348     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 70,593     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-07 4 A $0.00 $0 D/D 20,327 170,526     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 66,061     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 5,928 48,910     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 79,608     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 52,832     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 8,448 83,190     -
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 4,743 21,606     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-07 4 A $0.00 $0 D/D 4,743 24,882     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-07 4 A $0.00 $0 D/D 7,707 41,046     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 1,853 11,641     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-06 4 A $0.00 $0 D/D 14,842 63,479     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-06 4 A $0.00 $0 D/D 41,488 150,199     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-06 4 A $0.00 $0 D/D 15,254 58,947     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 42,982     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 72,494     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 45,718     -
  3274 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us